Intracavitary Therapeutics for Pleural Malignancies

Clinics in Chest Medicine

Volumn 34, Issue 3, 2013, Pages 501-513

  Haas, Andrew R ^a   Sterman, Daniel H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Intracavitary therapeutics; Malignancy; Pleural; Tumors

Indexed keywords

ADENOVIRUS VECTOR; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BACTERIAL ANTIGEN; BETA INTERFERON; BLEOMYCIN; CISPLATIN; COMPLEMENTARY DNA; CYTOKINE; DOCETAXEL; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; LIPOSOME; METHOTREXATE; MITOMYCIN; MITOXANTRONE; OLIGONUCLEOTIDE; PARVOVIRUS VECTOR; PEMETREXED; PICIBANIL; PLATINUM COMPLEX; PROTEIN P53; PROTEIN TYROSINE KINASE; RETROVIRUS VECTOR; SCH 721015; SMALL INTERFERING RNA; STAPHYLOCOCCAL SUPERANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MECHANISM; EOSINOPHILIA; HUMAN; HYPERTHERMIC THERAPY; INNATE IMMUNITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PLEURA CANCER; PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SINGLE DRUG DOSE; SUICIDE GENE; SURVIVAL TIME; SYSTEMIC THERAPY; THYMOMA; THYMUS CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

INTRACAVITARY THERAPEUTICS; MALIGNANCY; PLEURAL; TUMORS;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; PLEURAL NEOPLASMS; PLEURODESIS;

EID: 84883054473     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.04.007     Document Type: Review

References (81)

1. Sterman D.H., Albelda S.M. Advances in the diagnosis, evaluation and management of malignantpleural mesothelioma. Respirology 2005, 10:266-283.
2. Bone G. Postoperative empyema and survival in lung cancer. Br Med J 1973, 2(5859):178.
3. Ruckdeschel J.C., Codish S.D., Stranahan A., et al. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. NEngl J Med 1972, 287(20):1013-1017.
4. Vaisrub S. Empyema in lung cancer-the cloud with a silver lining. JAMA 1973, 224(12):1644.
5. Minasian H., Lewis C.T., Evans S.J. Influence of postoperative empyema on survival after pulmonary resection for bronchogenic carcinoma. Br Med J 1978, 2(6148):1329-1331.
6. Lawaetz O., Halkier E. The relationship between postoperative empyema and long-term survival after pneumonectomy. Results of surgical treatment of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1980, 14(1):113-117.
7. Pastorino U., Valente M., Piva L., et al. Empyema following lung cancer resection: risk factors and prognostic value on survival. Ann Thorac Surg 1982, 33(4):320-323.
8. McKneally M.F., Maver C., Lininger L., et al. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. JThorac Cardiovasc Surg 1981, 81(4):485-492.
9. Bakker W., Nijhuis-Heddes J.M., Wever A.M., et al. Postoperative intrapleural BCG in lung cancer: lack of efficacy and possible enhancement of tumour growth. Thorax 1981, 36(11):870-874.
10. Bakker W., Nijhuis-Heddes J.M., van der Velde E.A. Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother 1986, 22(2):155-159.
11. Refaely Y., Simansky D.A., Paley M., et al. Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001, 72(2):366-370.
12. Pinto C., Marino A., Guaraldi M., et al. Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2001, 24(2):143-147.
13. Chang M.Y., Sugarbaker D.J. Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin 2004, 14(4):549-556.
14. Tilleman T.R., Richards W.G., Zellos L., et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. JThorac Cardiovasc Surg 2009, 138(2):405-411.
15. Tohda Y., Iwanaga T., Takada M., et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999, 45(3):197-204.
16. Shoji T., Tanaka F., Yanagihara K., et al. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest 2002, 121(3):821-824.
17. Su W.C., Kitagawa M., Xue N., et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology 2003, 64(1):18-24.
18. Matsuzaki Y., Edagawa M., Shimizu T., et al. Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis. Ann Thorac Surg 2004, 78(5):1769-1772. [discussion: 1772-3].
19. Jones D.R., Taylor M.D., Petroni G.R., et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. JThorac Oncol 2010, 5(1):75-81.
20. Fitzpatrick D.R., Peroni D.J., Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995, 12(5):455-460.
21. Fitzpatrick D.R., Bielefeldt-Ohmann H., Himbeck R.P., et al. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994, 11(1):29-44.
22. Jarnicki A.G., Musk A.W., Robinson B.W., et al. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett 1996, 103(1):1-9.
23. Lew F., Tsang P., Holland J.F., et al. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. JClin Immunol 1986, 6(3):225-233.
24. Kagan E. The alveolar macrophage: immune derangement and asbestos-related malignancy. Semin Oncol 1981, 8(3):258-267.
25. Henderson D.W., Attwood H.D., Constance T.J., et al. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol 1988, 12(4):367-384.
26. Astoul P., Viallat J.R., Laurent J.C., et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993, 103(1):209-213.
27. Christmas T.I., Manning L.S., Garlepp M.J., et al. Effect of interferon-alpha 2a on malignant mesothelioma. JInterferon Res 1993, 13(1):9-12.
28. Boutin C., Nussbaum E., Monnet I., et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994, 74(9):2460-2467.
29. Boutin C., Viallat J.R., Van Zandwijk N., et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991, 67(8):2033-2037.
30. Yanagawa H., Haku T., Hiramatsu K., et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother 1997, 45(2):93-99.
31. Goey S.H., Eggermont A.M., Punt C.J., et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995, 72(5):1283-1288.
32. Sartori S., Tombesi P., Tassinari D., et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. JClin Oncol 2004, 22(7):1228-1233.
33. Yamaguchi Y., Ohshita A., Kawabuchi Y., et al. Locoregional immunotherapy ofmalignant effusion from colorectal cancer usingthe streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes. Br J Cancer 2003, 89(10):1876-1884.
34. Ikehara M., Oshita F., Suzuki R., et al. Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa. JExp Ther Oncol 2004, 4(1):79-83.
35. Ren S., Terman D.S., Bohach G., et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest 2004, 126(5):1529-1539.
36. Wivel N.A., Wilson J.M. Methods of gene delivery. Hematol Oncol Clin North Am 1998, 12(3):483-501.
37. Curiel D.T., Pilewski J.M., Albelda S.M. Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol 1996, 14(1):1-18.
38. Nagy J.A., Shockley T.R., Masse E.M., et al. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther 1995, 2(6):402-410.
39. Yang L., Hwang R., Pandit L., et al. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg 1996, 224(3):405-414. [discussion: 414-7].
40. Batra R.K., Dubinett S.M., Henkle B.W., et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. JBiol Chem 1997, 272(18):11736-11743.
41. Monahan P.E., Samulski R.J. AAV vectors: is clinical success on the horizon?. Gene Ther 2000, 7(1):24-30.
42. Zhang W.W. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999, 6(2):113-138.
43. Yeh P., Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997, 11(8):615-623.
44. Wold W.S., Doronin K., Toth K., et al. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 1999, 11(4):380-386.
45. Smythe W.R., Hwang H.C., Amin K.M., et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective invitro drug sensitization system. Cancer Res 1994, 54(8):2055-2059.
46. Brody S.L., Jaffe H.A., Han S.K., et al. Direct invivo gene transfer and expression in malignant cells using adenovirus vectors. Hum Gene Ther 1994, 5(4):437-447.
47. Esandi M.C., van Someren G.D., Vincent A.J., et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 1997, 4(4):280-287.
48. Batra R.K., Dubinett S.M., Henkle B.W., et al. Adenoviral gene transfer is inhibited by soluble factors in malignant pleural effusions. Am J Respir Cell Mol Biol 2000, 22(5):613-619.
49. Sterman D.H., Treat J., Litzky L.A., et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9(7):1083-1092.
50. Chesnoy S., Huang L. Structure and function of lipid-DNA complexes for gene delivery. Annu Rev Biophys Biomol Struct 2000, 29:27-47.
51. Nagamachi Y., Tani M., Shimizu K., et al. Suicidal gene therapy for pleural metastasis of lung cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Cancer Gene Ther 1999, 6(6):546-553.
52. Hortobagyi G.N., Ueno N.T., Xia W., et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. JClin Oncol 2001, 19(14):3422-3433.
53. Tiberghien P. Use of suicide genes in gene therapy. JLeukoc Biol 1994, 56(2):203-209.
54. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000, 60(15):3989-3999.
55. Elshami A.A., Saavedra A., Zhang H., et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system invitro. Gene Ther 1996, 3(1):85-92.
56. Pope I.M., Poston G.J., Kinsella A.R. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997, 33(7):1005-1016.
57. Kolls J., Freeman S., Ramesh R., et al. The treatment of malignant pleural mesothelioma with gene modified cancer cells: a phase I study. Am J Respir Crit Care Med 1998, 157:A563.
58. Schwarzenberger P., Harrison L., Weinacker A., et al. Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. JLa State Med Soc 1998, 150(4):168-174.
59. Schwarzenberger P., Byrne P., Gaumer R., et al. Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. Cancer Gene Ther 2011, 18(12):906-912.
60. Harrison L.H., Schwarzenberger P.O., Byrne P.S., et al. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000, 70(2):407-411.
61. Smythe W.R., Hwang H.C., Elshami A.A., et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995, 222(1):78-86.
62. Smythe W.R., Kaiser L.R., Hwang H.C., et al. Successful adenovirus-mediated gene transfer in an invivo model of human malignant mesothelioma. Ann Thorac Surg 1994, 57(6):1395-1401.
63. Hwang H.C., Smythe W.R., Elshami A.A., et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat invivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995, 13(1):7-16.
64. Elshami A.A., Kucharczuk J.C., Zhang H.B., et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1996, 7(2):141-148.
65. Molnar-Kimber K.L., Sterman D.H., Chang M., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9(14):2121-2133.
66. Sterman D.H., Molnar-Kimber K., Iyengar T., et al. Apilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000, 7(12):1511-1518.
67. Leong C.C., Marley J.V., Loh S., et al. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. Immunol Cell Biol 1997, 75(4):356-359.
68. Addison C.L., Braciak T., Ralston R., et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995, 92(18):8522-8526.
69. Mukherjee S., Haenel T., Himbeck R., et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000, 7(5):663-670.
70. Rosso R., Rimoldi R., Salvati F., et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988, 45(3):253-256.
71. Cascinu S., Isidori P.P., Fedeli A., et al. Experience with intrapleural natural beta interferon in the treatment of malignant pleural effusions. Tumori 1991, 77(3):237-238.
72. Odaka M., Sterman D.H., Wiewrodt R., et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001, 61(16):6201-6212.
73. Sterman D.H., Recio A., Carroll R.G., et al. Aphase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007, 13(15 Pt 1):4456-4466.
74. Sterman D.H., Recio A., Haas A.R., et al. Aphase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010, 18(4):852-860.
75. Sterman D.H., Haas A., Moon E., et al. Atrial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011, 184(12):1395-1399.
76. Selvaraj P., Yerra A., Tien L., et al. Custom designing therapeutic cancer vaccines: delivery of immunostimulatory molecule adjuvants by protein transfer. Hum Vaccin 2008, 4(5):384-388.
77. Vachani A., Moon E., Wakeam E., et al. Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010, 42(4):385-393.
78. Giuliano M., Catalano A., Strizzi L., et al. Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000, 5(6):591-596.
79. Dong M., Li X., Hong L.J., et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. JInt Med Res 2008, 36(6):1273-1278.
80. Zhao W.Z., Wang J.K., Li W., et al. Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer. Ai Zheng 2009, 28(12):1324-1327.
81. Haas A.R., Sterman D.H. Malignant pleural mesothelioma: Update on treatment options with a focus on novel therapies. Clin Chest Med 2013, 34(1):99-111.